Access to genomic data on cancer has raised hopes for rapid advances, but many worry about clinicians’ ability to effectively use the information.
Dr. Robert Califf became commissioner of the FDA in February. He brings to the job more than 30 years of experience in clinical trial research at Duke University Medical Center. Califf discusses his priorities and some of the controversies that swirled around his nomination.
Johnson & Johnson subsidiary Ethicon announced a deal to acquire NeuWave Medical, a privately held company that makes surgical oncology devices.
Cancer treatment provider 21st Century Oncology will settle with the federal government to end a dispute related to its radiation therapy testing, a company spokeswoman confirmed Thursday. It's the company's second settlement in three months.
There is “considerable variability,” and one of the most significant factors affecting quality of care is whether a patient is treated by a gynecologic oncologist at a high-volume facility, according to the report from the National Academies of Sciences, Engineering, and Medicine.
Spending for outpatient cancer drugs is rising, and a new analysis of private insurance claims suggests that's largely because providers are charging more for the drugs as hospitals employ more oncologists.
McKesson announced Thursday that it had acquired two oncology companies to bolster its specialty health segment. The combined transactions were valued at $1.2 billion, and are expected to close in the first quarter of fiscal 2017, pending customary closing conditions.
It's been well documented in the medical literature that hospitals that perform more procedures tend to have better outcomes. While most patients don't have a way to track which are the high-volume centers, the California Healthcare Foundation has done so for Golden State residents.
In light of the challenges seen since President Nixon launched the first "war on cancer" in 1971, experts say any new approach to cures, moonshot or otherwise, must get back to the basics. The oncology community agrees a coordinated approach could address the clinical research challenges.
Clinical pathways, lists meant to guide clinicians toward the optimal course of treatment, have reached the point of being an “unsustainable” administrative burden, according to the American Society of Clinical Oncology, and the process of developing them is laden with inadequacies and...
The American Society of Clinical Oncology says so-called clinical pathways created and distributed by payers and for-profit firms are laden with inadequacies and conflicts of interest.
Joseph Mallas has been named president and CEO of U.S. HealthWorks, an occupational-health and urgent-care subsidiary of San Francisco-based Dignity Health.